S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:CLSNCelsion Stock Price, Forecast & News

$1.10
-0.03 (-2.65 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.08
Now: $1.10
$1.15
50-Day Range
$1.05
MA: $2.26
$4.44
52-Week Range
$0.69
Now: $1.10
$6.50
Volume1.13 million shs
Average Volume1.84 million shs
Market Capitalization$36.56 million
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Read More
Celsion logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSN
CUSIPN/A
Phone609-896-9100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$0.63 per share

Profitability

Net Income$-16,850,000.00
Net Margins-3,908.00%

Miscellaneous

Employees29
Market Cap$36.56 million
Next Earnings Date8/14/2020 (Confirmed)
OptionableOptionable
$1.10
-0.03 (-2.65 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Celsion (NASDAQ:CLSN) Frequently Asked Questions

How has Celsion's stock price been impacted by Coronavirus?

Celsion's stock was trading at $0.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLSN stock has increased by 11.1% and is now trading at $1.10.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Celsion?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Celsion
.

When is Celsion's next earnings date?

Celsion is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Celsion
.

How can I listen to Celsion's earnings call?

Celsion will be holding an earnings conference call on Friday, August 14th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) released its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.03. The biotechnology company earned $0.13 million during the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative net margin of 3,908.00% and a negative return on equity of 120.14%.
View Celsion's earnings history
.

When did Celsion's stock split? How did Celsion's stock split work?

Celsion's stock reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLSN?

2 equities research analysts have issued 1 year price objectives for Celsion's shares. Their forecasts range from $4.00 to $4.00. On average, they expect Celsion's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 263.6% from the stock's current price.
View analysts' price targets for Celsion
.

Has Celsion been receiving favorable news coverage?

News stories about CLSN stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celsion earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about Celsion
.

Are investors shorting Celsion?

Celsion saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 204,400 shares, an increase of 49.9% from the December 15th total of 136,400 shares. Based on an average daily volume of 194,100 shares, the days-to-cover ratio is currently 1.1 days.
View Celsion's Short Interest
.

Who are some of Celsion's key competitors?

What other stocks do shareholders of Celsion own?

Who are Celsion's key executives?

Celsion's management team includes the following people:
  • Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 68)
  • Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 62)
  • Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 59)
  • Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 60)
  • Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 61)

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Who are Celsion's major shareholders?

Celsion's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.08%), Park Avenue Securities LLC (0.08%) and Total Investment Management Inc. (0.08%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper.
View institutional ownership trends for Celsion
.

Which institutional investors are buying Celsion stock?

CLSN stock was purchased by a variety of institutional investors in the last quarter, including Park Avenue Securities LLC, Envestnet Asset Management Inc., and Total Investment Management Inc.. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno, and Robert W Hooper.
View insider buying and selling activity for Celsion
.

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $1.10.

How big of a company is Celsion?

Celsion has a market capitalization of $36.56 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Celsion employs 29 workers across the globe.

What is Celsion's official website?

The official website for Celsion is www.celsion.com.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.